<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vestronidase alfa: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vestronidase alfa: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vestronidase alfa: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="115770" href="/d/html/115770.html" rel="external">see "Vestronidase alfa: Drug information"</a> and <a class="drug drug_patient" data-topicid="115771" href="/d/html/115771.html" rel="external">see "Vestronidase alfa: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F50786990"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Anaphylaxis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anaphylaxis has occurred with vestronidase alfa administration, as early as the first dose, therefore appropriate medical support should be readily available when administered. Closely observe patients during and for 60 minutes after vestronidase alfa infusion. Immediately discontinue the infusion if the patient experiences anaphylaxis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50828733"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Mepsevii</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F50811872"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Enzyme</span></li></ul></div>
<div class="block dop drugH1Div" id="F50835270"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd46599d-8d20-4c86-9e10-866c155c266d">Mucopolysaccharidosis VII</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mucopolysaccharidosis VII (MPS VII, Sly syndrome): Note:</b> Premedicate with nonsedating antihistamines with or without antipyretics 30 to 60 minutes prior to the start of the infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 4 mg/kg/dose every 2 weeks</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51220289"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, adjustment based on renal function is unlikely to be necessary as vestronidase alfa is not expected to be renally cleared.</p></div>
<div class="block dohp drugH1Div" id="F51220290"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, adjustment based on hepatic function is unlikely to be necessary as vestronidase alfa is degraded by proteolytic enzymes that are not restricted to hepatic tissue.</p></div>
<div class="block doa drugH1Div" id="F50835269"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="115770" href="/d/html/115770.html" rel="external">see "Vestronidase alfa: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premedicate with nonsedating antihistamines with/without antipyretics 30 to 60 minutes prior to the start of the infusion. Administer under supervision of a health care provider with the ability to manage anaphylaxis.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd46599d-8d20-4c86-9e10-866c155c266d">Mucopolysaccharidosis VII</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mucopolysaccharidosis VII (Sly syndrome): IV:</b> 4 mg/kg every 2 weeks.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990768"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, adjustment based on renal function is unlikely to be necessary as vestronidase alfa is not expected to be renally cleared.</p></div>
<div class="block doha drugH1Div" id="F50987917"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, adjustment based on hepatic function is unlikely to be necessary as vestronidase alfa is degraded by proteolytic enzymes that are not restricted to hepatic tissue.</p></div>
<div class="block adr drugH1Div" id="F50794791"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (may be neutralizing; antibody development did not appear to affect reduction in urinary glycosaminoglycans)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Swelling at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Miscellaneous: Febrile seizures</p></div>
<div class="block coi drugH1Div" id="F50786994"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F50835260"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Infusion site extravasation has been reported; infusion site swelling has also occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/anaphylactoid reactions: Hypersensitivity, including anaphylaxis, has occurred with administration; manifestations included respiratory distress, cyanosis, decreased oxygen saturation, and hypotension. Consider the risks and benefits of re-administering vestronidase alfa following anaphylaxis; in clinical trials, patients experiencing anaphylaxis were able to tolerate subsequent infusions without recurrence of anaphylaxis.</p></div>
<div class="block foc drugH1Div" id="F50828734"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mepsevii: Vestronidase alfa-vjbk 10 mg/5 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F50828732"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F51083818"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Mepsevii Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/5 mL (per mL): $632.88</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614668"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer IV over ~4 hours using an infusion set with an in-line low protein-binding 0.2-micron filter. Infuse the first 2.5% of total volume over the first hour (making sure to account for any dead space in the IV line); after the first hour, increase the infusion rate (as tolerated) to complete the infusion over the next 3 hours. Do not flush the line to avoid a rapid bolus of infused enzyme. Due to the low infusion rate in some patients, additional NS may be run through a separate line (piggyback or Y-site) to maintain sufficient IV flow to prevent clotting or line blockage. Do not infuse other products in same IV line. Discontinue the infusion immediately if severe reaction occurs, including anaphylaxis. Observe patient during, and for 60 minutes following, infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">May be an irritant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p></div>
<div class="block adm drugH1Div" id="F50835275"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse IV over ~4 hours; infuse the first 2.5% of total volume over the first hour (accounting for any dead space in IV line); after the first hour, increase infusion rate (as tolerated) to complete infusion over the next 3 hours. Administer using an infusion set with an in-line low protein-binding 0.2 micron filter. Do not flush the line to avoid a rapid bolus of infused enzyme; due to the low infusion rate, additional NS may be added through a separate line (piggyback or Y tube) to maintain sufficient IV flow to prevent clotting or line blockage. Do not infuse other products in same IV line. Discontinue the infusion immediately if severe reaction occurs, including anaphylaxis. Observe patient during and for at least 60 minutes following infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">May be an irritant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p></div>
<div class="block sts drugH1Div" id="F50835262"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store under refrigeration at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Protect from light. Following dilution use immediately; if this is not possible, the diluted solution may be stored up to 36 hours under refrigeration followed by up to 6 hours at room temperature ≤25°C (77°F). Infusion should be completed within 42 hours from time of dilution.</p></div>
<div class="block usep drugH1Div" id="F53571437"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of mucopolysaccharidosis VII (MPS VII, Sly syndrome) (FDA approved in pediatric patients [age not specified] and adults)</p></div>
<div class="block cyt drugH1Div" id="F50815378"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F50815375"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F50835258"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53571438"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for infusion/hypersensitivity reactions (during and for 60 minutes following completion of infusion). Monitor infusion site.</p></div>
<div class="block pha drugH1Div" id="F50835264"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Vestronidase alfa is a recombinant human beta-glucuronidase (GUS), which provides exogenous GUS enzyme for uptake into cellular lysosomes. Mannose-6-phosphate (M6P) residues on the oligosaccharide chains allow binding of the enzyme to cell surface receptors, leading to cellular uptake of the enzyme, targeting to lysosomes and subsequent catabolism of accumulated glycosaminoglycans (GAGs) in affected tissues.</p></div>
<div class="block phk drugH1Div" id="F50835265"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d,ss</sub>: 251 ± 140 mL/kg (range: 97 to 598 mL/kg).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Proteolytic degradation into small peptides and amino acids.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2.33 ± 0.75 hours (range: 0.86 to 3.03 hours).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F52903905"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Mepsevii</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Mepsevii</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Mepsevii</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Mepsevii</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Mepsevii</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Mepsevii</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Mepsevii (vestronidase alfa) [prescribing information]. Novato, CA: Ultragenyx Pharmaceutical Inc; December 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 118276 Version 35.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
